NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Jonas D, Van Scoyoc E, Gerrald K, et al. Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet]. Portland (OR): Oregon Health & Science University; 2011 Feb.

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations

Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].

Show details

Evidence Tables

Evidence Table 1. Key Question 1: Studies of pramlintide

Evidence Table 2. Key Question 1: Studies of sitagliptin and saxagliptin

Evidence Table 3. Key Question 1: Studies of exenatide and liraglutide

Evidence Table 4. Key Question 1: Studies of rosiglitazone and pioglitazone

Evidence Table 5. Key Question 1: Studies of fixed-dose combination products and dual therapy

Evidence Table 6. Key Question 1: Quality assessment of trials for Key Question 1

Evidence Table 7. Key Question 2: Studies of pramlintide

Evidence Table 8. Key Question 2: Studies of sitagliptin and saxagliptin

Evidence Table 9. Key Question 2: Studies of exenatide and liraglutide

Evidence Table 10. Key Question 2: Studies of rosiglitazone and pioglitazone

Evidence Table 11. Key Question 2: Studies of fixed-dose combination products and dual therapy

Evidence Table 12. Key Question 2: Quality assessment of trials for Key Question 2

Evidence Table 13. Key Question 3: All studies

Evidence Table 14. Key Question 3: Quality assessment of trials for Key Question 3

Evidence Table 15. Key Question 1: Systematic reviews

Evidence Table 16. Key Question 1: Quality assessment of systematic reviews

Evidence Table 17. Key Question 2: Systematic reviews

Evidence Table 18. Key Question 2: Quality assessment of systematic reviews

Evidence Table 19. Key Question 1: Observational studies

Evidence Table 20. Key Question 1: Quality assessment of observational studies

Evidence Table 21. Key Question 2: Observational studies

Evidence Table 22. Key Question 2: Quality assessment of observational studies

Abbreviations used in evidence tables

ACE

Angiotensin-converting enzyme

ACT

Active-control trial

AE

Adverse event

ALT

Alanine aminotransferase

ANCOVA

Analysis of covariance

ANOVA

Analysis of variance

ARB

Angiotensin receptor blockers

AST

Aspartate aminotransferase

BiAsp

Biphasic insulin aspart

bid

Twice daily

BMI

Body mass index

CCT

Controlled clinical trial

CHF

Congestive heart failure

CI

Confidence interval

CND

Cannot determine

CNS

Central nervous system

CPK

Creatine phosphokinase

CR

Controlled release

CrCl

Creatinine clearance

CV

Cardiovascular

CVD

Cardiovascular disease

CVS

Cardiovascular system

d

Day

DB

Double-blind

dL

Deciliter

DM

Diabetes mellitus

DPP-IV

Dipeptidyl peptidase IV

ECG

Electrocardiogram

EEG

Electroencephalogram

EF

Ejection fraction

ER

Extended release

FDA

US Food and Drug Administration

FU

Follow-up

g

Gram

GI

Gastrointestinal

GLP-1

Glucogon like peptide-1

GP

General practitioner

h

Hour

HbA1c

Glycosylated hemoglobin

HbA1c

Glycosylated hemoglobin

HDL

High-density lipoprotein

HDL-C

High density lipoprotein cholesterol

Hg

Mercury

HMO

Health maintenance organization

HR

Hazard ratio

HRQOL

Health-related quality of life

ICD-10

International Classification of Diseases, Tenth Revision

ICD-9

International Classification of Diseases, Ninth Revision

IR

Immediate release

ITT

Intention-to-treat

L

Liter

LA

Long acting

LDL

Low-density lipoprotein

LDL-C

Low-density lipoprotein cholesterol

LOCF

Last Observation Carried Forward

LS means

Least squares means

MANCOVA

Multivariate analysis of covariance

mcg

Microgram

mg

Milligram

MI

Myocardial Infarction

min

Minute

mL

Milliliter

mo

Month

N

Sample size (entire sample)

n

Subgroup sample size

NA

Not applicable

NR

Not reported

NS

Not significant

NSD

No significant difference

OAD

Oral antidiabetic

OR

Odds ratio

P

P value

P

Placebo

PCT

Placebo-controlled trial

PPY

Per person year

qd

Once daily

QOL

Quality of life

RCT

Randomized controlled trial

RR

Relative risk

SB

Single-blind

SCr

Serum creatinine

SD

Standard deviation

SE

Standard error

SR

Sustained release

T1D

Type 1 diabetes

T1DM

Type 1 diabetes mellitus

T2D

Type 2 diabetes

T2DM

Type 2 diabetes mellitus

TC

Total cholesterol

TG

Triglycerides

tid

Three times daily

TZD

Thiazolidinedione

VAS

Visual analog scale

vs.

Compared with (versus)

WD

Withdrawal

XR

Extended release

y

Year

Copyright © 2011, Oregon Health & Science University.
Bookshelf ID: NBK54206
PubReader format: click here to try

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...